EMA recommends authorisation of first medicine for Castleman's disease

The CHMP has recommended the granting of a MA for Sylvant (siltuximab), a medicine for the treatment of adult patients with multicentric Castleman’s disease.

26th March 2014

For more information or an estimate, contact us »